Fertility and Sterility
Volume 89, Issue 2 , Pages 368-374 , February 2008

Cryopreservation of supernumerary high quality embryos predicts favorable outcomes for patients undergoing repeated cycles of in vitro fertilization

Received 7 November 2006 ,Revised 20 February 2007 ,Accepted 8 March 2007.

References 

  1. Centers for Disease Control and Prevention. 2004 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 2006;
  2. Shapiro BS, Richter KS, Harris DC, Daneshmand ST. Dramatic declines in implantation and pregnancy rates in patients who undergo repeated cycles of in vitro fertilization with blastocyst transfer after one or more failed attempts. Fertil Steril. 2001;76:538–542
  3. Silberstein T, Trimarchi JR, Gonzalez L, Keefe DL, Blazar AS. Pregnancy outcome in in vitro fertilization decreases to a plateau with repeated cycles. Fertil Steril. 2005;84:1043–1045
  4. Kolibianakis EM, Devroey P. No decrease occurs in the number of COCs retrieved with repeated IVF cycles. Hum Reprod. 2004;19:1927–1928
  5. Hoveyda F, Engmann L, Steele J, Lopez Bernal A, Barlow DH. Ovarian response in three consecutive in vitro fertilization cycles. Fertil Steril. 2002;77:706–710
  6. Doldi N, Persico P, De Santis L, Rabellotti E, Papaleo E, Ferrari A. Consecutive cycles in in vitro fertilization–embryo transfer. Gynecol Endocrinol. 2005;20:132–136
  7. Kolibianakis E, Osmanagaoglu K, Camus M, Tournaye H, Van Steirteghem A, Devroey P. Effect of repeated assisted reproductive technology cycles on ovarian response. Fertil Steril. 2002;77:967–970
  8. Guzick DS, Wilkes C, Jones HW. Cumulative pregnancy rates for in vitro fertilization. Fertil Steril. 1986;46:663–667
  9. Meldrum DR, Silverberg KM, Bustillo M, Stokes L. Success rate with repeated cycles of in vitro fertilization–embryo transfer. Fertil Steril. 1998;69:1005–1009
  10. De Vries MJ, De Sutter P, Dhont M. Prognostic factors in patients continuing in vitro fertilization or intracytoplasmic sperm injection treatment and dropouts. Fertil Steril. 1999;72:674–678
  11. Padilla SL, Garcia JE. Effect of maternal age and number of in vitro fertilization procedures on pregnancy outcome. Fertil Steril. 1989;52:270–273
  12. Haan G, Bernardus RE, Hollanders JM, Leerentveld RA, Prak FM, Naaktgeboren N. Results of IVF from a prospective multicentre study. Hum Reprod. 1991;6:805–810
  13. Tan SL, Royston P, Campbell S, Jacobs HS, Betts J, Mason B, et al. Cumulative conception and livebirth rates after in-vitro fertilisation. Lancet. 1992;339:1390–1394
  14. Templeton A, Morris JK, Parslow W. Factors that affect outcome of in-vitro fertilisation treatment. Lancet. 1996;348:1402–1406
  15. FIVNAT (French In Vitro National). French National IVF Registry: analysis of 1986 to 1990 data. Fertil Steril. 1993;59:587–595
  16. Centers for Disease Control and Prevention. 1995 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1997;
  17. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2006;3:CD001750
  18. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod. 2000;15:526–531
  19. Bahceci M, Ulug U, Ben-Shlomo I, Erden HF, Akman MA. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. J Reprod Med. 2005;50:84–90
  20. Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod. 2000;15:1490–1498
  21. Check ML, Check JH, Choel JK, Davies E, Kiefer D. Effect of antagonists vs agonists on in vitro fertilization outcome. Clin Exp Obstet Gynecol. 2004;31:257–259
  22. Cheung LP, Lam PM, Lok IH, Chiu TT, Yeung SY, Tjer CC, et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod. 2005;20:616–621
  23. Hohmann FP, Macklon NS, Fauser BC. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab. 2003;88:166–173
  24. Moon SY, Ku SY, Kim SM, Jee BC, Suh CS, Choi YM, et al. Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone. J Obstet Gynaecol Res. 2005;31:227–235
  25. Marci R, Caserta D, Dolo V, Tatone C, Pavan A, Moscarini M. GnRH antagonist in IVF poor-responder patients: results of a randomized trial. Reprod Biomed Online. 2005;11:189–193
  26. Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 2001;75:38–45
  27. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril. 2000;73:314–320
  28. Rombauts L, Healy D, Norman RJ. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. Hum Reprod. 2006;21:95–103
  29. Zikopoulos K, Kaponis A, Adonakis G, Sotiriadis A, Kalantaridou S, Georgiou I, et al. A prospective randomized study comparing gonadotropin-releasing hormone agonists or gonadotropin-releasing hormone antagonists in couples with unexplained infertility and/or mild oligozoospermia. Fertil Steril. 2005;83:1354–1362
  30. The European Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod. 2001;16:644–651

PII: S0015-0282(07)00617-6

doi: 10.1016/j.fertnstert.2007.03.031

Fertility and Sterility
Volume 89, Issue 2 , Pages 368-374 , February 2008

Article Tools

* Image Usage & Resolution